



2021 JCA-AACR Precision Cancer Medicine International Conference Program

Program DAY 1	Date/Time (JST)	Date/Time (PDT)	Date/Time (EDT)
<p>Keynote Session:</p> <p>Chair: Dr. Hiroyuki Mano (National Cancer Center, Tokyo, Japan) (JCA)</p> <p>Chair: Dr. Elaine R. Mardis (Nationwide Children’s Hospital, Columbus, Ohio, USA) (AACR)</p>			
<p>KS-1: National Platform for Cancer Precision Medicine in Japan</p> <p>Dr. Hiroyuki Mano (National Cancer Center, Tokyo, Japan) (JCA)</p>	<p>9/11 Sat. 8:00-8:55</p>	<p>9/10 Fri. 16:00-16:55</p>	<p>9/10 Fri. 19:00-19:55</p>
<p>KS-2: Genomics-Guided Pediatric Cancer Precision Medicine: New Developments</p> <p>Dr. Elaine R. Mardis (Nationwide Children’s Hospital, Columbus, Ohio, USA) (AACR)</p>			

<p>Plenary 1: Liquid Biopsy</p> <p>Chair: Dr. Takayuki Yoshino (National Cancer Center Hospital East, Chiba, Japan)</p> <p>Chair: Dr. Lillian L. Siu (UHN Princess Margaret Cancer Centre, Toronto, Ontario, Canada)</p>			
<p>PL1-1: Circulating DNA for Liquid Biopsies: Coming in Different Sizes and Shapes</p> <p>Dr. Dennis Lo (Chinese University of Hong Kong, Hong Kong, China-Hong Kong)</p>			
<p>PL1-2: Exosomal PD-L1: Role in Immune Suppression and Potential Application in Immune Oncology</p> <p>Dr. Wei Guo (University of Pennsylvania, Philadelphia, Pennsylvania, USA)</p>	<p>9/11 Sat. 9:00-10:45</p>	<p>9/10 Fri. 17:00-18:45</p>	<p>9/10 Fri. 20:00-21:45</p>
<p>PL1-3: Liquid Biopsy to Enable MRD Detection and Interception and the Precise Use of Immunotherapy</p> <p>Dr. Lillian L. Siu (UHN Princess Margaret Cancer Centre, Toronto, Ontario, Canada)</p>			
<p>PL1-4: Near Future Forecast of Precision Oncology using Liquid Biopsy Technology</p> <p>Dr. Takayuki Yoshino (National Cancer Center Hospital East, Chiba, Japan)</p>			
Break			

<p>Program 1: Somatic Mutations in Precancerous Tissue</p> <p>Chair: Dr. Benjamin L. Ebert (Dana-Farber Cancer Institute, Boston, Massachusetts, USA)</p> <p>Chair: Dr. Seishi Ogawa (Kyoto University, Kyoto, Japan)</p>	<p>Program 2: Novel Platforms for Precision Medicine</p> <p>Chair: Dr. Jeffrey W. Tyner (OHSU Knight Cancer Institute, Portland, Oregon, USA)</p> <p>Chair: Dr. Shinichi Yachida (Osaka University, Osaka, Japan)</p>			
<p>PG01-1: Clonal Hematopoiesis and the Origins of Blood Cancers</p> <p>Dr. Benjamin L. Ebert (Dana-Farber Cancer Institute, Boston, Massachusetts, USA)</p>	<p>PG02-1: Spatial Immunoprofiling for Stratification of Cancer Patients for Immunotherapy</p> <p>Dr. Shohei Koyama (National Cancer Center, Tokyo)</p>	<p>9/11 Sat. 11:00-12:30</p>	<p>9/10 Fri. 19:00-20:30</p>	<p>9/10 Fri. 22:00-23:30</p>
<p>PG01-2: Clonal Expansion in Apparently Normal Tissues</p> <p>Dr. Seishi Ogawa (Kyoto University, Kyoto, Japan)</p>	<p>PG02-2: Functional Genomics for Therapeutic Innovation in Hematologic Malignancies</p> <p>Dr. Jeffrey W. Tyner (OHSU Knight Cancer Institute, Portland, Oregon, USA)</p>			
<p>PG01-3: Somatic Mutations in Normal Bronchial Epithelia</p> <p>Dr. Kenichi Yoshida (Wellcome Sanger Institute, Saffron Walden, United Kingdom)</p>	<p>PG02-3: Human Fecal Microbiome-Based Biomarkers for Colorectal Cancer (Live only)</p> <p>Dr. Shinichi Yachida (Osaka University, Osaka, Japan)</p>			
<p>Break</p>				

<p>SS-1A: Leading with Data: Tumor-informed ctDNA Testing across Cancer Types Sponsored by Natera</p> <p>Chair: Dr. Hiroya Taniguchi (Aichi Cancer Center)</p> <p>Speaker: Dr. Angel Rodriguez (Natera)</p>	<p>SS-1B: Genomes for Precision Oncology Sponsored by Illumina K.K.</p> <p>Chair: Dr. Hiroyuki Mano (National Cancer Center, Tokyo)</p> <p>Speaker: Dr. David Bentley (Illumina, Inc.)</p>	<p>9/11 Sat. 12:40-13:10</p>	<p>9/10 Fri. 20:40-21:10</p>	<p>9/10 Fri. 23:40-1:10(9/11)</p>
<p>SS-2A: A New Therapeutic Cancer Vaccine inducing Multifunctional Immunity, Artificial Adjuvant Vector Cells Sponsored by Nippon Becton Dickinson Company, Ltd.</p> <p>Chair: Dr. Norimitsu Kadowaki (Faculty of Medicine, Kagawa University)</p> <p>Speaker: Dr. Shin-ichiro Fujii (Team Leader, Laboratory for Immunotherapy, Center for Integrative Medical Sciences, RIKEN Vice Director, Program for Drug Discovery and Medical Technology Platforms, RIKEN)</p>	<p>SS-2B: Comprehensive Cancer Gene Profiling for Precision Oncology Sponsored by Konica Minolta Precision Medicine Japan, Inc.</p> <p>Chair: Dr. Shinji Kohsaka (National Cancer Center, Tokyo)</p> <p>Speaker: Dr. Hiroyuki Aburatani (Research Center for Advanced Science and Technology, The University of Tokyo)</p>	<p>9/11 Sat. 13:15-13:45</p>	<p>9/10 Fri. 21:15-21:45</p>	<p>9/11 Sat. 1:15-1:45</p>

<p>SS-3A: Leading the Way in Target Enrichment: Exceptional Performance, Improved Efficiency and Rapid Customization of Targeted Methylation Sequencing Sponsored by Twist Bioscience</p> <p>Chair: Mr. Mark Dupal (Senior Sales Director, Asia Pacific, Twist Bioscience)</p> <p>Speaker: Mr. Bryan Hoglund (Senior Manager, NGS Business Solutions, Twist Bioscience)</p>	<p>SS-3B: Considerations for Incorporating Biomarkers into Real World Dataset Sponsored by Syapse Inc.</p> <p>Chair: Dr. Hiroyuki Mano (National Cancer Center, Tokyo)</p> <p>Speaker: Dr. Anna Berry (Syapse)</p>	<p>9/11 Sat. 13:50-14:20</p>	<p>9/10 Fri. 21:50-22:20</p>	<p>9/11 Sat. 1:50-2:20</p>
--	---	-----------------------------------	-----------------------------------	---------------------------------

Break

<p>Program 3: Drug Resistance</p> <p>Chair: Dr. Ryohei Katayama (The Cancer Chemotherapy Center, JFCR, Tokyo, Japan)</p>	<p>Program 4: Germline Predisposition</p> <p>Chair: Prof. Katsutoshi Oda (Division of Integrative Genomics, Graduate School of Medicine, The University of Tokyo Director, Department of Clinical Genomics The University of Tokyo Hospital, Japan)</p>	<p>9/11 Sat. 14:30-16:00</p>	<p>9/10 Fri. 22:30- 0:00(9/11)</p>	<p>9/11 Sat. 1:30-3:00</p>
<p>PG03-1: HDAC3 is a Targetable Mediator of Therapeutic Resistance in Non-small Cell Lung Cancer</p> <p>Dr. Reuben J. Shaw (Salk Institute, La Jolla, California, USA)</p>	<p>PG04-1: Large-scale Germline Sequencing of Hereditary Cancer Genes in >60,000 Cancer Patients and Controls</p> <p>Dr. Yukihide Momozawa (RIKEN Center for Integrative Medical Sciences Laboratory for Genotyping Development, Kanagawa, Japan)</p>			
<p>PG03-2: Mechanisms of Intrinsic Resistance Mediated by Tumor Microenvironment and Secreted Proteins in Non-small Cell Lung Cancer</p> <p>Dr. Ryohei Katayama (The Cancer Chemotherapy Center, JFCR, Tokyo, Japan)</p>	<p>PG04-2: High Throughput Functional Analysis for the Clinical Annotation in Cancer Genome Medicine</p> <p>Dr. Shinji Kohsaka (National Cancer Center, Tokyo)</p>			
<p>PG03-3: RAS Proteins in Human Disease</p> <p>Dr. Frank McCormick (UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, USA)</p>	<p>PG04-3: Germline Predispositions to Hematologic Malignancies</p> <p>Dr. Courtney D. DiNardo (UT MD Anderson Cancer Center, Houston, Texas, USA)</p>			

ePoster presentation is available all the time during the conference as well as On-demand distribution by December 31

Program DAY 2	Date/Time (JST)	Date/Time (PDT)	Date/Time (EDT)
<p>Plenary 2: Immuno-oncology</p> <p>Chair: Dr. Hiroyoshi Nishikawa (National Cancer Center, Tokyo)</p> <p>Chair: Dr. Elizabeth M. Jaffee (Johns Hopkins University, Baltimore, Maryland, USA)</p>			
<p>PL2-1: Integrity of the IFN and MHC Signaling Pathways in Tumor Immunity and Therapy</p> <p>Dr. Weiping Zou (University of Michigan, Ann Arbor, Michigan, USA)</p>			
<p>PL2-2: Immunosuppression by Regulatory T Cells in the Tumor Microenvironment</p> <p>Dr. Hiroyoshi Nishikawa (National Cancer Center, Tokyo)</p>	9/12 Sun. 8:00-9:45	9/11 Sat. 16:00-17:45	9/11 Sat. 19:00-20:45
<p>PL2-3: Pancreatic Cancer Treatment in the Era of Precision Immunotherapy</p> <p>Dr. Elizabeth M. Jaffee (Johns Hopkins University, Baltimore, Maryland, USA)</p>			
<p>PL2-4: Epigenetic Insights into T Cell Longevity for Optimal Adoptive Immunotherapy</p> <p>Dr. Yuki Kagoya (Aichi Cancer Center Research Institute, Nagoya, Japan)</p>			
Break			

<p>Program 5: Hematology</p> <p>Chair: Dr. Keisuke Kataoka (Keio University School of Medicine, Tokyo, Japan)</p> <p>Chair: Dr. Elli Papaemmanuil (Memorial Sloan Kettering Cancer Center, New York, New York, USA)</p>	<p>Program 6: Research Focused on Asian Cancers</p> <p>Chair: Dr. Patrick Tan (Cancer Science Institute of Singapore, NUS, Singapore, Singapore)</p> <p>Chair: Dr. Nilofer S. Azad (Johns Hopkins University, Baltimore, Maryland, USA)</p>			
<p>PG05-1: Multicellular Ecosystem in HTLV-1 Viral Carcinogenesis Revealed by Multi-omics Single-cell Analysis</p> <p>Dr. Keisuke Kataoka (Keio University School of Medicine, Tokyo, Japan)</p>	<p>PG06-1: Recent Advances in the (Epi)genomic Landscape of Gastric Cancer</p> <p>Dr. Patrick Tan (Cancer Science Institute of Singapore, NUS, Singapore, Singapore)</p>	<p>9/12 Sun. 10:00-11:30</p>	<p>9/11 Sat. 18:00-19:30</p>	<p>9/11 Sat. 21:00-22:30</p>
<p>PG05-2: Population Genomic Studies to Advance Precision Medicine Practices in Myeloid Neoplasms</p> <p>Dr. Elli Papaemmanuil (Memorial Sloan Kettering Cancer Center, New York, New York, USA)</p>	<p>PG06-2: Trans-ethnic Driver Landscape of Gastric Cancer</p> <p>Dr. Tatsuhiro Shibata (The Institute of Medical Science, The University of Tokyo, Tokyo, Japan)</p>			
<p>PG05-3: Understanding and Targeting Aberrant Splicing in Leukemias</p> <p>Dr. Akihide Yoshimi (Cancer RNA Research Unit, National Cancer Center Research Institute, Tokyo, Japan)</p>	<p>PG06-3: The Emerging Understanding of Phenotypes of Biliary Tract Cancers</p> <p>Dr. Nilofer S. Azad (Johns Hopkins University, Baltimore, Maryland, USA)</p>			
<p>Break</p>				

<p>SS-4A: WGS and WES with DNBSEQ Technology for Precision Oncology Sponsored by JAPAN MGI TECH CO., LTD</p> <p>Chair: Dr. Hiroyuki Mano (National Cancer Center, Tokyo)</p> <p>Speaker: Mr. Toby Huang (BD Director at MGI)</p> <p>Speaker: Prof. Steven Jones (University of British Columbia)</p>	<p>SS-4B: Fecal Microbiome Profiling in the SCRUM-Japan MONSTAR-SCREEN Project Reveals Novel Connections between Tumor and Gut Microbiota Sponsored by bitBiome, Inc.</p> <p>Chair: Mr. Sunao Fujioka (CBO (Chief Business Officer), bitBiome, Inc.)</p> <p>Speaker: Dr. Riu Yamashita (Translational Informatics, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center)</p>	<p>9/12 Sun. 11:40-12:10</p>	<p>9/11 Sat. 19:40-20:10</p>	<p>9/11 Sat. 22:40-23:10</p>
<p>SS-5A: Real World Data Insights for the Advancement of Precision Medicine Sponsored by Flatiron Health K.K.</p> <p>Chair: Dr. Takayuki Yoshino (Department of Gastrointestinal Oncology, National Cancer Center Hospital East)</p> <p>Speaker: Dr. Ivy Altomare (Medical Director, Flatiron Health Inc.)</p>	<p>SS-5B: Precision Medicine in Cancer Sponsored by Denka Company Limited</p> <p>Chair: Dr. Hiroyuki Mano (National Cancer Center, Tokyo)</p> <p>Speaker: Prof. Raju Kucherlapati (Harvard Medical School)</p>	<p>9/12 Sun. 12:15-12:45</p>	<p>9/11 Sat. 20:15-20:45</p>	<p>9/11 Sat. 23:15-23:45</p>

<p>SS-6A: Web-based Treatment Decision Support Tool for Precision Medicine Sponsored by Molecular Health</p> <p>Chair: Prof. Manabu Muto (Kyoto University, Graduate School of Medicine)</p> <p>Speaker: Prof. Masashi Kanai (Kyoto University, Graduate School of Medicine)</p>		<p>9/12 Sun. 12:50-13:20</p>	<p>9/11 Sat. 20:50-21:20</p>	<p>9/11 Sat. 23:50-0:20(9/12)</p>
<p>Break</p>				

<p>Program 7: Cancer Model Systems</p> <p>Chair: Dr. Akinobu Hamada (National Cancer Center, Tokyo)</p> <p>Chair: Dr. Calvin J. Kuo (Stanford University, Stanford, California, USA)</p>	<p>Program 8: Real-World Evidence in Precision Medicine</p> <p>Chair: Dr. Takashi Kohno (National Cancer Center, Tokyo)</p>			
<p>PG07-1: Modeling Tumor Tissue Complexity with 3D Bioprinting</p> <p>Dr. Rosalie C. Sears (Oregon Health & Science University, Portland, Oregon, USA)</p>	<p>PG08-1: Utilization of Large Scale Real-world Tumor Profiling Data Obtained from Daily Cancer Treatment</p> <p>Dr. Takashi Kohno (National Cancer Center, Tokyo)</p>	<p>9/12 Sun. 13:30-15:00</p>	<p>9/11 Sat. 21:30-23:00</p>	<p>9/12 Sun. 0:30-2:00</p>
<p>PG07-2: Organoid Modeling of Tumor Genomes and Microenvironments (Live only)</p> <p>Dr. Calvin J. Kuo (Stanford University, Stanford, California, USA)</p>	<p>PG08-2: Real-World Evidence in K-MASTER Cancer Precision Medicine Program</p> <p>Dr. Yeul Hong Kim (Korea University, Seoul, Korea)</p>			
<p>PG07-3: Drug Discovery and Development Research for New Anticancer Agents based on Pharmacokinetic and Pharmacodynamic Analysis using Patient-derived Xenograft (J-PDX) Library</p> <p>Dr. Akinobu Hamada (National Cancer Center, Tokyo)</p>	<p>PG08-3: AACR Project GENIE: Powering Precision Medicine through International Data-Sharing</p> <p>Dr. Philippe L. Bedard (UHN Princess Margaret Cancer Centre, USA)</p>			
<p>Break</p>				

<p>Program 9: AI in Precision Medicine</p> <p>Chair: Dr. Shunpei Ishikawa (The University of Tokyo, Tokyo, Japan)</p> <p>Chair: Dr. Trey Ideker (UC San Diego, La Jolla, California, USA)</p>	<p>Program 10: Pediatric Cancer</p> <p>Chair: Dr. Junko Takita (Kyoto University, Kyoto, Japan)</p> <p>Chair: Dr. Michelle Haber (Children's Cancer Institute, Sydney, Australia)</p>	<p>9/12 Sun. 15:15-16:45</p>	<p>9/11 Sat. 23:15- 0:45(9/12)</p>	<p>9/12 Sun. 2:15 -3:45</p>
<p>PG09-1: Building the Mind of Cancer</p> <p>Dr. Trey Ideker (UC San Diego, La Jolla, California, USA)</p>	<p>PG10-1: Integrated Genetic and Epigenetic Analysis of Pediatric Cancers</p> <p>Dr. Junko Takita (Kyoto University, Kyoto, Japan)</p>			
<p>PG09-2: Universal Encoding of Cancer Histology by Deep Neural Network</p> <p>Dr. Shunpei Ishikawa (The University of Tokyo, Tokyo, Japan)</p>	<p>PG10-2: Zero Childhood Cancer: A Whole of System National Approach to Improving Outcomes of Australian Children with Cancer through Precision Medicine</p> <p>Dr. Michelle Haber (Children's Cancer Institute, Sydney, Australia)</p>			
<p>PG09-3: Convergence of Machine Learning and Genomics for Precision Cancer Medicine</p> <p>Dr. Eliezer Van Allen (Dana-Farber Cancer Institute, Boston, Massachusetts, USA)</p>	<p>PG10-3: Genomic Variants in Pediatric Cancer: Model for Relapse, Precision Medicine, and Data Sharing Ecosystem</p> <p>Dr. Jinghui Zhang (St. Jude Children's Research Hospital, Memphis, Tennessee, USA)</p>			